Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04929483 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
A Phase 2 study, sponsored by 89bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 222
- Enrollment target
NCT04929483 is a Phase 2 study that has completed, run by 89bio. The registered enrollment target is 222 participants.
The verdict
NCT04929483, a Phase 2 study, has completed, sponsored by 89bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 222 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled study that will evaluate the safety, efficacy, tolerability of BIO89-100 in patients with biopsy-confirmed fibrosis stages F2-F3 NASH.
Interventions
- DRUG Placebo
- DRUG BIO89-100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2021-06-04 |
| Est. Completion | 2024-10-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04929483
The ClinicalTrials.gov registry entry for NCT04929483 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is 89bio, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04929483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04929483 about?
NCT04929483 is a clinical study titled "Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)". This is a randomized, double-blind, placebo-controlled study that will evaluate the safety, efficacy, tolerability of BIO89-100 in patients with biopsy-confirmed fibrosis stages F2-F3 NASH.
What is the current status of trial NCT04929483?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 222 participants. The study started on 2021-06-04. Estimated completion is 2024-10-08.
What interventions are being tested in trial NCT04929483?
The interventions under investigation include: Placebo (DRUG), BIO89-100 (DRUG).
Who is sponsoring clinical trial NCT04929483?
This trial is sponsored by 89bio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.